nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE8A—G alpha (s) signalling events—CGA—conduct disorder	0.0554	0.0616	CbGpPWpGaD
Flavoxate—PDE8B—G alpha (s) signalling events—CGA—conduct disorder	0.0554	0.0616	CbGpPWpGaD
Flavoxate—PDE7B—G alpha (s) signalling events—CGA—conduct disorder	0.0494	0.0549	CbGpPWpGaD
Flavoxate—PDE7A—G alpha (s) signalling events—CGA—conduct disorder	0.0459	0.051	CbGpPWpGaD
Flavoxate—PDE4D—TSH signaling pathway—CGA—conduct disorder	0.0431	0.0479	CbGpPWpGaD
Flavoxate—PDE4C—G alpha (s) signalling events—CGA—conduct disorder	0.0299	0.0332	CbGpPWpGaD
Flavoxate—PDE4D—G alpha (s) signalling events—CGA—conduct disorder	0.026	0.0289	CbGpPWpGaD
Flavoxate—PDE4A—G alpha (s) signalling events—CGA—conduct disorder	0.0248	0.0275	CbGpPWpGaD
Flavoxate—PDE4B—G alpha (s) signalling events—CGA—conduct disorder	0.0229	0.0255	CbGpPWpGaD
Flavoxate—PDE7A—brain—conduct disorder	0.0174	0.173	CbGeAlD
Flavoxate—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.0159	0.0177	CbGpPWpGaD
Flavoxate—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.0157	0.0174	CbGpPWpGaD
Flavoxate—PDE7B—brain—conduct disorder	0.0152	0.151	CbGeAlD
Flavoxate—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0134	0.0149	CbGpPWpGaD
Flavoxate—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0132	0.0147	CbGpPWpGaD
Flavoxate—PDE8B—brain—conduct disorder	0.0121	0.12	CbGeAlD
Flavoxate—PDE8A—GPCR downstream signaling—CGA—conduct disorder	0.0114	0.0126	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—CGA—conduct disorder	0.0114	0.0126	CbGpPWpGaD
Flavoxate—PDE4C—brain—conduct disorder	0.0112	0.112	CbGeAlD
Flavoxate—PDE8A—brain—conduct disorder	0.0109	0.108	CbGeAlD
Flavoxate—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.0104	0.0115	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—CGA—conduct disorder	0.0103	0.0115	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—CGA—conduct disorder	0.0103	0.0115	CbGpPWpGaD
Flavoxate—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0102	0.0114	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—CGA—conduct disorder	0.0101	0.0113	CbGpPWpGaD
Flavoxate—PDE4D—brain—conduct disorder	0.00985	0.0982	CbGeAlD
Flavoxate—PDE7A—GPCR downstream signaling—CGA—conduct disorder	0.00942	0.0105	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—CGA—conduct disorder	0.0092	0.0102	CbGpPWpGaD
Flavoxate—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00872	0.00969	CbGpPWpGaD
Flavoxate—PDE4A—brain—conduct disorder	0.00871	0.0869	CbGeAlD
Flavoxate—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00861	0.00957	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—CGA—conduct disorder	0.00855	0.0095	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.00697	0.00775	CbGpPWpGaD
Flavoxate—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00681	0.00757	CbGpPWpGaD
Flavoxate—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00673	0.00748	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—DRD4—conduct disorder	0.00636	0.00707	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—DRD4—conduct disorder	0.00636	0.00707	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—CGA—conduct disorder	0.00614	0.00682	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—CGA—conduct disorder	0.0061	0.00677	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—CGA—conduct disorder	0.0061	0.00677	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—DRD4—conduct disorder	0.00578	0.00642	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—DRD4—conduct disorder	0.00578	0.00642	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—DRD4—conduct disorder	0.00567	0.0063	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—CGA—conduct disorder	0.00557	0.00619	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CGA—conduct disorder	0.00543	0.00604	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CGA—conduct disorder	0.00534	0.00594	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—DRD4—conduct disorder	0.00527	0.00586	CbGpPWpGaD
Flavoxate—PDE4B—brain—conduct disorder	0.00519	0.0518	CbGeAlD
Flavoxate—CHRM2—brain—conduct disorder	0.00516	0.0515	CbGeAlD
Flavoxate—PDE7B—Signaling by GPCR—DRD4—conduct disorder	0.00515	0.00572	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CGA—conduct disorder	0.00508	0.00565	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CGA—conduct disorder	0.00505	0.00561	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—WASF1—conduct disorder	0.00489	0.00543	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—WASF1—conduct disorder	0.00489	0.00543	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CGA—conduct disorder	0.00485	0.00539	CbGpPWpGaD
Flavoxate—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00482	0.00536	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—DRD4—conduct disorder	0.00479	0.00532	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CGA—conduct disorder	0.0047	0.00523	CbGpPWpGaD
Flavoxate—CHRM1—brain—conduct disorder	0.0047	0.0468	CbGeAlD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0047	0.00522	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00463	0.00515	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CGA—conduct disorder	0.00462	0.00513	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.00455	0.00506	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—WASF1—conduct disorder	0.00435	0.00484	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CGA—conduct disorder	0.00427	0.00475	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—HTR2A—conduct disorder	0.00415	0.00461	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—HTR2A—conduct disorder	0.00415	0.00461	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—WASF1—conduct disorder	0.00405	0.0045	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.00399	0.00443	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—HTR2A—conduct disorder	0.00377	0.00419	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—HTR2A—conduct disorder	0.00377	0.00419	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.00375	0.00416	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—HTR2A—conduct disorder	0.0037	0.00411	CbGpPWpGaD
Flavoxate—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00363	0.00403	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.00358	0.00397	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.00353	0.00392	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—HTR2A—conduct disorder	0.00344	0.00382	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—DRD4—conduct disorder	0.00344	0.00382	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—DRD4—conduct disorder	0.00341	0.00379	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—DRD4—conduct disorder	0.00341	0.00379	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—HTR2A—conduct disorder	0.00336	0.00373	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CGA—conduct disorder	0.00329	0.00366	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.00326	0.00363	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—HTR2A—conduct disorder	0.00312	0.00347	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—DRD4—conduct disorder	0.00312	0.00347	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00307	0.00341	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—DRD4—conduct disorder	0.00304	0.00338	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00303	0.00337	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—DRD4—conduct disorder	0.00299	0.00332	CbGpPWpGaD
Flavoxate—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00296	0.00329	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CGA—conduct disorder	0.00287	0.00318	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—DRD4—conduct disorder	0.00285	0.00316	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—DRD4—conduct disorder	0.00283	0.00314	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CGA—conduct disorder	0.00273	0.00303	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—DRD4—conduct disorder	0.00272	0.00302	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—WASF1—conduct disorder	0.00264	0.00293	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—DRD4—conduct disorder	0.00263	0.00293	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00263	0.00292	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0026	0.00288	CbGpPWpGaD
Flavoxate—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00259	0.00288	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—DRD4—conduct disorder	0.00259	0.00287	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CGA—conduct disorder	0.00252	0.0028	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—DRD4—conduct disorder	0.00239	0.00266	CbGpPWpGaD
Flavoxate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00232	0.00257	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—WASF1—conduct disorder	0.0023	0.00255	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—HTR2A—conduct disorder	0.00224	0.00249	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—HTR2A—conduct disorder	0.00223	0.00248	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—HTR2A—conduct disorder	0.00223	0.00248	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—WASF1—conduct disorder	0.00219	0.00243	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—HTR2A—conduct disorder	0.00204	0.00226	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—WASF1—conduct disorder	0.00202	0.00225	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.00202	0.00225	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.002	0.00223	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.002	0.00223	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00199	0.00222	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—HTR2A—conduct disorder	0.00199	0.00221	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00198	0.0022	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.00198	0.0022	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—HTR2A—conduct disorder	0.00195	0.00217	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—HTR2A—conduct disorder	0.00186	0.00206	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—HTR2A—conduct disorder	0.00185	0.00205	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—DRD4—conduct disorder	0.00184	0.00205	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.00183	0.00204	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.00181	0.00201	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—HTR2A—conduct disorder	0.00177	0.00197	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—HTR2A—conduct disorder	0.00172	0.00191	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00172	0.00191	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00169	0.00188	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—HTR2A—conduct disorder	0.00169	0.00187	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—DRD4—conduct disorder	0.0016	0.00178	CbGpPWpGaD
Flavoxate—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00157	0.00174	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—HTR2A—conduct disorder	0.00156	0.00173	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—DRD4—conduct disorder	0.00153	0.0017	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—DRD4—conduct disorder	0.00141	0.00157	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00131	0.00145	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—EP300—conduct disorder	0.0013	0.00144	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00129	0.00143	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—HTR2A—conduct disorder	0.0012	0.00134	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—EP300—conduct disorder	0.00118	0.00131	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—EP300—conduct disorder	0.00118	0.00131	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00113	0.00126	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.00112	0.00124	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CGA—conduct disorder	0.00108	0.0012	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00107	0.00119	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—EP300—conduct disorder	0.00105	0.00117	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—HTR2A—conduct disorder	0.00105	0.00116	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—DRD4—conduct disorder	0.00103	0.00114	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00101	0.00113	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—HTR2A—conduct disorder	0.000997	0.00111	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—EP300—conduct disorder	0.000978	0.00109	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—HTR2A—conduct disorder	0.000922	0.00102	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—WASF1—conduct disorder	0.000869	0.000965	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.000857	0.000953	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.000738	0.000821	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.000729	0.00081	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	0.00067	0.000745	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.000662	0.000736	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—EP300—conduct disorder	0.000637	0.000708	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DRD4—conduct disorder	0.000607	0.000675	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.000599	0.000666	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—EP300—conduct disorder	0.000555	0.000616	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—EP300—conduct disorder	0.000528	0.000587	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—EP300—conduct disorder	0.000489	0.000543	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HTR2A—conduct disorder	0.000396	0.00044	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000391	0.000435	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EP300—conduct disorder	0.00021	0.000233	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000207	0.00023	CbGpPWpGaD
